AG
FPRX

Artal Group’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Artal Group’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,000
Closed -$2.05M – 135
2017
Q3 		$2.05M Sell
50,000
-100,000
-67% -$3.14M 0.04% 92
2017
Q2 		$4.52M Buy
+150,000
New +$4.68M 0.08% 67

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Artal Group's FPRX Position: Q4 2017 in Review

Artal Group sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2017, closing a stake of 50,000 shares — an estimated $2.05M sold.

Artal Group first reported a position in FPRX in Q2 2017 and held it in 2 quarters. The position peaked at $4.52M in Q2 2017. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

  • Artal Group reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Artal Group sold 50,000 Five Prime Therapeutics, Inc. shares in Q4 2017, an estimated $2.05M.
  • Artal Group first reported a position in Five Prime Therapeutics, Inc. in Q2 2017 and held it in 2 quarters.
  • Artal Group's Five Prime Therapeutics, Inc. position peaked at $4.52M in Q2 2017.
  • 137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Artal Group's 13F filing for Q4 2017, filed 9 Feb 2018.